Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE)

我们还没有针对COVID-19患者的任何治疗方法，因此我们正在进行一项临床试验，以测试可能有效的药物。大多数COVID - 19病例在社区得到管理，我们必须找到有助于减少住院和加速康复的治疗方法。50岁及以上有潜在健康问题的人群和65岁及以上人群因疑似COVID-19感染而出现并发症的风险通常更大。因此，我们将邀请这两组人参加我们的试验。我们将评估的第一种药物是羟氯喹，它已经用于治疗其他疾病，但尚未在社区中疑似covid -19患者中进行测试。因此，我们尚不清楚给予COVID-19患者羟氯喹（或我们在试验中纳入的任何未来治疗方法）是否有助于减少住院需求或加速康复。最初纳入研究的所有人都将接受COVID-19检测，并将接受通常的最佳护理，或者接受通常的最佳护理加上我们正在测试的药物羟氯喹。我们将在第一次试验中纳入3000人。

We do not yet have any treatments for COVID-19 patients, so we are now running a clinical trial to test out drugs which may work. Most COVID 19 cases are managed in the community and it is essential that we find treatments that help reduce hospital admission and speed recovery. The risk of complications from suspected COVID-19 infection is generally greater in people aged 50 years and older with underlying health conditions and in those aged 65 years and older. Therefore, we will ask these two groups to take part in our trial. The first drug we will evaluate is hydroxychloroquine, which is already used for other illnesses, but but it has not been tested in patients with suspected COVIS-19 in the community. Therefore, we do not yet know if hydroxychloroquine, (or any future treatments that we include in the trial), given to COVID-19 patients, will help reduce the need for hospitalisation or speed up recovery. All people initially included in the study will have a test for COVID-19, and will either receive usual best care, or usual best care plus the drug we are testing, currently hydroxychloroquine. We will include 3000 people in the study in the first instance.